These results suggest that, in order to be attacked by “self-immunity”, tumor cells need to be reprogrammed by specific “effector” components, such as HSP70, HMGB1 and CRT, resulting in activating vaccinated DCs in vitro or enhancing tumor immunogenicity in vivo. Here, HMGB1 is linked to neoplasm.